Keensight Capital’s Acquisition of Inke

Clifford Chance has advised Neuraxpharm on the deal. Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Permira’s Acquisition of Neuraxpharm

Clifford Chance advised Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders on the sale of Spanish pharmaceutical...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

ENI’s Agreement With Azora Capital

Clifford Chance has advised ENI, while Uría Menéndez has advised Azora Capital on the deal. ENI signed an agreement with Azora Capital for the acquisition of...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here